These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Sharma A; Hill A; Kurbatova E; van der Walt M; Kvasnovsky C; Tupasi TE; Caoili JC; Gler MT; Volchenkov GV; Kazennyy BY; Demikhova OV; Bayona J; Contreras C; Yagui M; Leimane V; Cho SN; Kim HJ; Kliiman K; Akksilp S; Jou R; Ershova J; Dalton T; Cegielski P; Lancet Infect Dis; 2017 Jul; 17(7):707-715. PubMed ID: 28499828 [TBL] [Abstract][Full Text] [Related]
24. From multidrug- to extensively drug-resistant tuberculosis: upward trends as seen from a 15-year nationwide study. Stoffels K; Allix-Béguec C; Groenen G; Wanlin M; Berkvens D; Mathys V; Supply P; Fauville-Dufaux M PLoS One; 2013; 8(5):e63128. PubMed ID: 23671662 [TBL] [Abstract][Full Text] [Related]
25. Management of Multidrug-Resistant Tuberculosis. Daley CL; Caminero JA Semin Respir Crit Care Med; 2018 Jun; 39(3):310-324. PubMed ID: 30071546 [TBL] [Abstract][Full Text] [Related]
26. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832 [TBL] [Abstract][Full Text] [Related]
27. Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children. Schaaf HS; Garcia-Prats AJ; du Preez K; Rautenbach C; Hesseling AC Int J Tuberc Lung Dis; 2016 Sep; 20(9):1249-56. PubMed ID: 27510254 [TBL] [Abstract][Full Text] [Related]
28. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336 [TBL] [Abstract][Full Text] [Related]
29. Antituberculosis Drug Resistance in Pulmonary Isolates of Mycobacterium tuberculosis, Cuba 2012-2014. Lemus D; Echemendía M; Díaz R; Llanes MJ; Suárez L; Marrero A MEDICC Rev; 2017 Jan; 19(1):10-15. PubMed ID: 28225540 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558 [TBL] [Abstract][Full Text] [Related]
32. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis. Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736 [TBL] [Abstract][Full Text] [Related]
33. Prevalence and factors associated with multidrug-resistant tuberculosis in South India. Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551 [TBL] [Abstract][Full Text] [Related]
34. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. Centers for Disease Control and Prevention (CDC) MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162 [TBL] [Abstract][Full Text] [Related]
35. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Wright A; Zignol M; Van Deun A; Falzon D; Gerdes SR; Feldman K; Hoffner S; Drobniewski F; Barrera L; van Soolingen D; Boulabhal F; Paramasivan CN; Kam KM; Mitarai S; Nunn P; Raviglione M; Lancet; 2009 May; 373(9678):1861-73. PubMed ID: 19375159 [TBL] [Abstract][Full Text] [Related]
36. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. Porwal C; Kaushik A; Makkar N; Banavaliker JN; Hanif M; Singla R; Bhatnagar AK; Behera D; Pande JN; Singh UB PLoS One; 2013; 8(2):e55299. PubMed ID: 23390524 [TBL] [Abstract][Full Text] [Related]
37. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Smith SE; Kurbatova EV; Cavanaugh JS; Cegielski JP Int J Tuberc Lung Dis; 2012 Feb; 16(2):203-5. PubMed ID: 22136739 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Dalton T; Cegielski P; Akksilp S; Asencios L; Campos Caoili J; Cho SN; Erokhin VV; Ershova J; Gler MT; Kazennyy BY; Kim HJ; Kliiman K; Kurbatova E; Kvasnovsky C; Leimane V; van der Walt M; Via LE; Volchenkov GV; Yagui MA; Kang H; ; Akksilp R; Sitti W; Wattanaamornkiet W; Andreevskaya SN; Chernousova LN; Demikhova OV; Larionova EE; Smirnova TG; Vasilieva IA; Vorobyeva AV; Barry CE; Cai Y; Shamputa IC; Bayona J; Contreras C; Bonilla C; Jave O; Brand J; Lancaster J; Odendaal R; Chen MP; Diem L; Metchock B; Tan K; Taylor A; Wolfgang M; Cho E; Eum SY; Kwak HK; Lee J; Lee J; Min S; Degtyareva I; Nemtsova ES; Khorosheva T; Kyryanova EV; Egos G; Perez MT; Tupasi T; Hwang SH; Kim CK; Kim SY; Lee HJ; Kuksa L; Norvaisha I; Skenders G; Sture I; Kummik T; Kuznetsova T; Somova T; Levina K; Pariona G; Yale G; Suarez C; Valencia E; Viiklepp P Lancet; 2012 Oct; 380(9851):1406-17. PubMed ID: 22938757 [TBL] [Abstract][Full Text] [Related]
39. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117 [TBL] [Abstract][Full Text] [Related]